Typhlitis associated with docetaxel treatment.
Cardenal
F
F
Montes
A
A
Llort
G
G
Seguí
J
J
Mesía
R
R
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002429:Cecal Diseases / Q000139:chemically induced / Q000209:etiology* / Q000382:microbiology / Q000473:pathology; D000077143:Docetaxel; D004761:Enterocolitis, Pseudomembranous / Q000382:microbiology* / Q000473:pathology; D017809:Fatal Outcome; D006801:Humans; D007077:Ileal Diseases / Q000139:chemically induced / Q000209:etiology* / Q000382:microbiology / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009336:Necrosis / Q000209:etiology; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives*; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel